Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
McKinsey
McKesson
Colorcon
Boehringer Ingelheim

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

VISIPAQUE 320 Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Visipaque 320, and when can generic versions of Visipaque 320 launch?

Visipaque 320 is a drug marketed by Ge Healthcare and is included in two NDAs.

The generic ingredient in VISIPAQUE 320 is iodixanol. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the iodixanol profile page.

Drug patent expirations by year for VISIPAQUE 320
Recent Clinical Trials for VISIPAQUE 320

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
BayerPhase 4
Duke Clinical Research InstitutePhase 4
INC ResearchPhase 4

See all VISIPAQUE 320 clinical trials

Pharmacology for VISIPAQUE 320
Synonyms for VISIPAQUE 320
1,3-Benzenedicarboxamide, 5,5'-((2-hydroxy-1,3-propanediyl)bis(acetylimino))bis(N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-
1,3-Benzenedicarboxamide, 5,5'-[(2-hydroxy-1,3- propanediyl)bis(acetylimino)]bis[N,N'-bis(2,3- dihydroxypropyl)-2,4,6-triiodo-
2-5410-3A
2-541O-3A
339I112
5-[[3-[[3,5-bis[2,3-bis(oxidanyl)propylcarbamoyl]-2,4,6-tris(iodanyl)phenyl]-ethanoyl-amino]-2-oxidanyl-propyl]-ethanoyl-amino]-N1,N3-bis[2,3-bis(oxidanyl)propyl]-2,4,6-tris(iodanyl)benzene-1,3-dicarboxamide
5-[acetyl-[3-[N-acetyl-3,5-bis(2,3-dihydroxypropylcarbamoyl)-2,4,6-triiodo-anilino]-2-hydroxy-propyl]amino]-N1,N3-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-benzene-1,3-dicarboxamide
5-[acetyl-[3-[N-acetyl-3,5-bis(2,3-dihydroxypropylcarbamoyl)-2,4,6-triiodoanilino]-2-hydroxypropyl]amino]-1-N,3-N-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
5-[acetyl-[3-[N-acetyl-3,5-bis[(2,3-dihydroxypropylamino)-oxomethyl]-2,4,6-triiodoanilino]-2-hydroxypropyl]amino]-N1,N3-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
5-{N-[3-(N-{3,5-bis[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl}acetamido)-2-hydroxypropyl]acetamido}-1-N,3-N-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
5,5'-((2-Hydroxytrimethylene)bis(acetylimino))bis(N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide)
5,5'-(2-hydroxypropane-1,3-diyl)bis(acetylazanediyl)bis(N1,N3-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide)
5,5'-[(2-hydroxypropane-1,3-diyl)bis(acetylimino)]bis[N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide]
92339-11-2
A844203
AB00513936
AB00513936_02
AC-7610
AC1L1GKH
AKOS015895607
AN-8826
BCP11111
BPBio1_000919
BRD-A08660406-001-01-8
BSPBio_000835
C-23647
CAS-92339-11-2
CC-29560
CCG-213207
CCRIS 7567
CHEBI:31705
CHEMBL1200507
CTK8G0329
D01474
DB01249
DSSTox_CID_25523
DSSTox_GSID_45523
DSSTox_RID_80929
DTXSID2045523
EC 618-837-0
FT-0627254
FT-0645028
GP8799
HMS1570J17
HMS2097J17
HMS3714J17
HSDB 8076
HW8W27HTXX
Indixanol
iodixanol
Iodixanol (JAN/USP/INN)
Iodixanol [USAN:BAN:INN]
Iodixanol [USAN:USP:INN:BAN]
Iodixanolum
Iodixanolum [Latin]
Lodixanol
LS-29753
NBQNWMBBSKPBAY-UHFFFAOYSA-N
NCGC00016958-01
NCGC00179408-01
NCGC00179408-03
NSC-760069
NSC760069
OptiPrep
OptiPrep(TM) Density Gradient Medium, used for cell and subcellular organelle isolation
Pharmakon1600-01503835
Prestwick0_000848
Prestwick1_000848
Prestwick2_000848
Prestwick3_000848
SCHEMBL21546
SPBio_002756
SR-01000872678
SR-01000872678-1
SR-01000872678-2
Tox21_110711
Tox21_110711_1
UNII-HW8W27HTXX
Visipaque
Visipaque (TN)
Visipaque 270
Visipaque; Iodixanolum

US Patents and Regulatory Information for VISIPAQUE 320

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare VISIPAQUE 320 iodixanol INJECTABLE;INJECTION 020351-002 Mar 22, 1996 RX Yes Yes   Start Trial   Start Trial   Start Trial
Ge Healthcare VISIPAQUE 320 iodixanol INJECTABLE;INJECTION 020808-002 Aug 29, 1997 RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VISIPAQUE 320

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge Healthcare VISIPAQUE 320 iodixanol INJECTABLE;INJECTION 020351-002 Mar 22, 1996   Start Trial   Start Trial
Ge Healthcare VISIPAQUE 320 iodixanol INJECTABLE;INJECTION 020808-002 Aug 29, 1997   Start Trial   Start Trial
Ge Healthcare VISIPAQUE 320 iodixanol INJECTABLE;INJECTION 020808-002 Aug 29, 1997   Start Trial   Start Trial
Ge Healthcare VISIPAQUE 320 iodixanol INJECTABLE;INJECTION 020351-002 Mar 22, 1996   Start Trial   Start Trial
Ge Healthcare VISIPAQUE 320 iodixanol INJECTABLE;INJECTION 020808-002 Aug 29, 1997   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Colorcon
Johnson and Johnson
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.